CGRP and Painful Pathologies Other than Headache

Walsh, David A.; McWilliams, Daniel F.

doi:10.1007/164_2019_242

Cited by 14 publications

(12 citation statements)

References 163 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies described the role of CGRP in both peripheral and central pain mechanisms including arthritis, migraine, nociceptive and neuropathic pain 44‐47 . In the current study, CGRP levels were significantly increased in sciatic nerve tissues 14 days after CCI induction (Figure 2A,B).…”

Section: Discussionsupporting

confidence: 59%

“…A number of studies described the role of CGRP in both peripheral and central pain mechanisms including arthritis, migraine, nociceptive and neuropathic pain. [44][45][46][47] In the current study, CGRP levels were significantly increased in sciatic nerve tissues 14 days after CCI induction (Figure 2A,B). This finding is supported by Zou et al 48 who showed that CGRP is up-regulated following sciatic nerve chronic constriction injuries in rats.…”

Section: Discussionsupporting

confidence: 58%

See 1 more Smart Citation

Renin‐angiotensin system blockade modulates both the peripheral and central components of neuropathic pain in rats: Role of calcitonin gene–related peptide, substance P and nitric oxide

Hegazy

Rezq

Fahmy

2020

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Neuropathic pain (NP) is defined as "the pain caused by a lesion or disease of the somatosensory nervous system". 1 This broad definition covers peripheral and central aspects of pain. The peripheral nerve injury can lead to maladaptation at every point through the pain axis, 2 and hence, profound CNS alterations and central sensitization can occur. 3 However, it has been suggested that central sensitization acts rather as an amplifier of the peripheral signals, and not an independent pain generator in peripheral neuropathic pain conditions. 2 Unfortunately, the existence of different pathological conditions leading to the development of neuropathic pain 4 makes it more difficult to identify an effective and reliable treatment. 5

show abstract

Section: Discussionsupporting

confidence: 59%

Section: Discussionsupporting

confidence: 58%

Renin‐angiotensin system blockade modulates both the peripheral and central components of neuropathic pain in rats: Role of calcitonin gene–related peptide, substance P and nitric oxide

Hegazy

Rezq

Fahmy

2020

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Glutamate binds to postsynaptic NMDAR receptor; CGRP acts on postsynaptic CGRP1 receptor; substance P binds to neurokinin-1 (NK1) G-protein-coupled receptor, and finally, signal pathways such as PKA and PKC are activated and lead to central sensitization [ 36 ]. CGRP is widely expressed in the CNS and plays a role in the amygdala and other brain stem areas to enhance the nociceptive signal [ 37 ]. The microglia and astrocytes in the spinal cord are activated after the peripheral nervous system is stimulated by injury and enter a state of enhanced response related to pain, producing cytokines such as TNF- α , interleukin-1 (IL-1), and IL-6 [ 24 , 38 ].…”

Section: Cns Regulation Mechanismsmentioning

confidence: 99%

Pain Mechanism in Rheumatoid Arthritis: From Cytokines to Central Sensitization

Cao

Fan

Yin

2020

Mediators of Inflammation

View full text Add to dashboard Cite

Pain is the most common symptom in patients with rheumatoid arthritis (RA). Although in recent years, through the implementation of targeted treatment and the introduction of disease-modifying antirheumatic drugs (DMARDs), the treatment of RA patients has made a significant progress, a large proportion of patients still feel pain. Finding appropriate treatment to alleviate the pain is very important for RA patients. Current research showed that, in addition to inflammation, RA pain involves peripheral sensitization and abnormalities in the central nervous system (CNS) pain regulatory mechanisms. This review summarized the literature on pain mechanisms of RA published in recent years. A better understanding of pain mechanisms will help to develop new analgesic targets and deploy new and existing therapies.

show abstract

“…9 There are studies in the literature evaluating the relationship between CGRP and pain in different diseases. 10 However, although there is chronic pain in FM, to the best of our knowledge, there is no study in the literature that has evaluated serum CGRP levels in FM. However, evaluation of the serum level of CGRP alone may not be sufficient to understand the role of CGRP in the pathogenesis of FM.…”

mentioning

confidence: 99%

Serum Calcitonin Gene-Related Peptide and Receptor Protein Levels in Patients With Fibromyalgia Syndrome: A Cross-Sectional Study

et al. 2020

View full text Add to dashboard Cite

Objectives This study aims to compare the serum calcitonin gene-related peptide (CGRP) and CGRP receptor protein levels between patients with fibromyalgia syndrome (FM) and healthy control subjects. Patients and methods The study included 88 patients (7 males, 81 females; mean age 44.5±9.1 years; range, 20 to 72 years) newly-diagnosed with FM according to the 2010 American College of Rheumatology criteria and 88 healthy volunteers (6 males, 82 females; mean age 43.0±6.1 years; range, 20 to 57 years). Venous blood samples were collected from both groups for the measurement of the levels of serum CGRP and CGRP receptor proteins (receptor component protein [RCP], receptor activity modifying protein 1 [RAMP 1] and calcitonin receptor-like receptor [CLR]). Results A comparison of the serum CGRP, CLR and RCP levels of the FM and control groups revealed a statistically significant difference (p=0.001, p=0.005, p=0.001, respectively). The difference between the groups in respect of the serum RAMP 1 levels was not statistically significant (p=0.107). Conclusion The serum CGRP, CLR and RCP levels were found to be higher in the FM patients, but no difference was determined between the FM patients and the healthy control group in respect of the RAMP 1 level. These results can be of guidance for further clinical studies of the etiopathogenesis and treatment of FM.

show abstract

CGRP and Painful Pathologies Other than Headache

Cited by 14 publications

References 163 publications

Renin‐angiotensin system blockade modulates both the peripheral and central components of neuropathic pain in rats: Role of calcitonin gene–related peptide, substance P and nitric oxide

Renin‐angiotensin system blockade modulates both the peripheral and central components of neuropathic pain in rats: Role of calcitonin gene–related peptide, substance P and nitric oxide

Pain Mechanism in Rheumatoid Arthritis: From Cytokines to Central Sensitization

Serum Calcitonin Gene-Related Peptide and Receptor Protein Levels in Patients With Fibromyalgia Syndrome: A Cross-Sectional Study

Contact Info

Product

Resources

About